Table 3.
Univariate and multivariate analysis of overall survival
| Clinical parameter |
Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|---|
| n (% ) | Median (months) # | P value | HR (95% CI) | P value | |
| Age |
|
|
0, 248 |
|
|
| < 65 |
38 (82, 6%) |
70, 1% |
|
|
|
| ≥ 65 |
8 (17, 4%) |
75, 0% |
|||
| Histopathologic cell type |
|
|
0, 043* |
NS |
NS |
| Serous |
24 (52, 2%) |
62, 5% |
|
|
|
| Others |
22 (47, 8%) |
80, 8% |
|||
| Residual tumor size |
|
|
0, 134 |
|
|
| <1 cm |
19 (41, 3%) |
81, 1% |
|
|
|
| > 1 cm |
27 (58, 7%) |
55, 9% |
|||
| Performance status (ECOG) |
|
|
0, 276 |
|
|
| 0-1 |
43 (93, 5%) |
71, 2% |
|
|
|
| 2 |
3 (6, 5%) |
66, 6% |
|||
| Tumor grade |
|
|
0, 498 |
|
|
| G1, G2 |
21 (45, 6%) |
32, 6 |
|
|
|
| G3, unknown |
25 (54, 4%) |
40, 4 |
|||
| Sensitivity to first-line chemotherapy |
|
|
<0, 0001* |
16, 84 (5, 07-55, 98) |
<0, 0001* |
| Resistant (<6 months) |
26 (35, 1%) |
21, 7% |
|
|
|
| Sensitive (>6 months) |
48 (64, 9%) |
93, 4% |
|||
| E-cadherin membranous |
|
|
0, 472 |
|
|
| Negative |
7 (15, 2%) |
50, 0 |
|
|
|
| Positive |
39 (84, 8%) |
35, 7 |
|||
| E-cadherin cytoplasmic |
1 (2, 2%) |
- |
- |
|
|
| Negative |
45 (97, 8%) |
|
|
|
|
| Positive |
|
||||
| β-catenin membranous |
|
|
0, 039* |
NS |
NS |
| Normal |
21 (45, 6%) |
22, 2 |
|
|
|
| Decreased |
25 (54, 4%) |
62, 2 |
|||
| β-catenin cytoplasmic |
|
|
0, 916 |
|
|
| Negative |
27 (58, 7%) |
32, 6 |
|
|
|
| Positive |
19 (41, 3%) |
40, 1 |
|||
| β-catenin nuclear |
|
- |
- |
|
|
| Negative |
46 (100, 0%) |
|
|
|
|
| Positive |
0 (0, 0%) |
||||
| WNT-1 |
|
|
0, 846 |
|
|
| Normal |
31 (67, 4%) |
33, 7 |
|||
| Decreased | 15 (32, 6%) | 40, 5 | |||
#If median was not achieved, the results were described as a percentage of patients with 2-year OS; NS- non significant; *The value of the probability of a statistically significant (p <0.05); CI-confidence interval; HR- hazard ratio; ECOG- The Eastern Cooperative Oncology Group scale of performance status.